Background The mechanisms underlying altered susceptibility and propensity to severe Coronavirus disease 2019 (COVID-19) disease in at-risk groups such as patients with chronic obstructive pulmonary disease (COPD) are poorly understood. Inhaled corticosteroids (ICSs) are widely used in COPD, but the extent to which these therapies protect or expose patients to risk of severe COVID-19 is unknown. Objective The aim of this study was to evaluate the effect of ICSs following pulmonary expression of the SARS-CoV-2 viral entry receptor angiotensin-converting enzyme-2 (ACE2). Methods We evaluated the effect of ICS administration on pulmonary ACE2 expression in vitro in human airway epithelial cell cultures and in vivo in mouse models of ICS administration. Mice deficient in the type I IFN-α/β receptor ( Ifnar1 −/− ) and administration of exogenous IFN-β were used to study the functional role of type-I interferon signaling in ACE2 expression. We compared sputum ACE2 expression in patients with COPD stratified according to use or nonuse of ICS. Results ICS administration attenuated ACE2 expression in mice, an effect that was reversed by exogenous IFN-β administration, and Ifnar1 −/− mice had reduced ACE2 expression, indicating that type I interferon contributes mechanistically to this effect. ICS administration attenuated expression of ACE2 in airway epithelial cell cultures from patients with COPD and in mice with elastase-induced COPD-like changes. Compared with ICS nonusers, patients with COPD who were taking ICSs also had reduced sputum expression of ACE2 . Conclusion ICS therapies in COPD reduce expression of the SARS-CoV-2 entry receptor ACE2. This effect may thus contribute to altered susceptibility to COVID-19 in patients with COPD. Graphical abstract
【저자키워드】 COVID-19, viral infection, COVID-19, Coronavirus disease 2019, inhaled corticosteroids, COPD, ACE2, Angiotensin-converting enzyme-2, BEC, Bronchial epithelial cell, BSG, Basigin, COPD, Chronic obstructive pulmonary disease, FP, Fluticasone propionate, GR, Glucocorticoid receptor, ICS, Inhaled corticosteroid, ISG, Interferon-stimulated gene, TMPRSS2, Transmembrane serine protease 2, 【초록키워드】 coronavirus disease, Coronavirus disease 2019, ACE2, Corticosteroids, therapy, severe COVID-19, susceptibility, risk, sputum, viral entry, inhaled corticosteroids, type I interferon, airway, COPD, Viral, mice, Cell culture, Patient, Inhaled, interferon signaling, receptor, IFNAR1, group, Mouse models, angiotensin-converting enzyme-2, mouse model, ACE2 expression, disease, expression, epithelial, mechanism, pulmonary disease, Angiotensin-converting enzyme, administration, angiotensin, chronic obstructive pulmonary disease, Elastase, epithelial cell, obstructive pulmonary disease, changes, Abstract, severe coronavirus disease, IFN-β, type I, entry receptor, SARS-CoV-2 entry receptor, human airway, IFN-α/β, exogenous IFN, ICSs, objective, reduce expression, inhaled corticosteroid, PROTECT, Result, evaluated, reduced, functional, were used, contribute, human airway epithelial, evaluate the effect, reversed, stratified, chronic obstructive, COVID-19 in patient, ICS, ICS therapy, the SARS-CoV-2, 【제목키워드】 Corticosteroids, receptor ACE2, inhaled corticosteroid, downregulate, the SARS-CoV-2,